Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK (GSK) Tops Q2 Earnings and Revenue Estimates
08:05am, Wednesday, 31'st Jul 2024
GSK (GSK) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $1 per share. This compares to earnings of $0.97 per share a year ago.
GSK's better-than-expected results overshadowed by Zantac litigation
05:45am, Wednesday, 31'st Jul 2024
GSK shares fell Wednesday as investors concerns' about lawsuits surrounding the pharmaceutical giant's discontinued heartburn drug Zantac outweighed any positive impacts from its better-than-expected
GSK forecast upgrade fails to impress the market
03:29am, Wednesday, 31'st Jul 2024
GSK PLC (LSE:GSK, NYSE:GSK) has raised its annual earnings and sales forecasts after a strong second-quarter performance driven by cancer and HIV treatments. However, the performance singularly failed
GSK raises annual profit and sales forecast after second quarter beat
02:11am, Wednesday, 31'st Jul 2024
British drugmaker GSK raised its annual earnings and sales forecasts on Wednesday and posted second-quarter results that beat market expectations, boosted by its cancer and HIV portfolio.
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
02:35pm, Tuesday, 30'th Jul 2024
Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.
3 Biotech Names With Potential Catalysts By Year End
03:32pm, Monday, 29'th Jul 2024
The huge sector rotation we have seen in the market over the past few weeks has significantly benefited the SPDR® S&P Biotech ETF. If this trend continues, small-cap names within the sector should co
GSK reaches confidential settlement in Illinois
04:14am, Monday, 29'th Jul 2024
GSK PLC (LSE:GSK, NYSE:GSK) said it has reached a confidential settlement with Ronald Kimbrow resolving the case he filed in Illinois state court, which is part of the drug giant's long-running Zanta
GSK's vaccine receives positive European Medicines Agency opinion
03:53am, Monday, 29'th Jul 2024
GSK PLC's (LSE:GSK, NYSE:GSK) respiratory syncytial virus vaccine, Arexvy, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use to exten
GSK settles another Illinois Zantac lawsuit
03:37am, Monday, 29'th Jul 2024
British drugmaker GSK on Monday said it has agreed to confidentially settle a lawsuit in Illinois alleging its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements t
Here's Why GSK (GSK) is a Strong Momentum Stock
10:51am, Friday, 26'th Jul 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EU regulator recommends use of GSK's RSV shot in adults aged 50 to 59
07:12am, Friday, 26'th Jul 2024
The European Union health regulator on Friday recommended expanded use of GSK's respiratory syncytial virus (RSV) vaccine in adults aged between 50 and 59.
GSK Stock Before Q2 Earnings: To Buy or Not to Buy?
12:00pm, Wednesday, 24'th Jul 2024
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix to drive second-quarter sales performance.
GSK (GSK) Earnings Expected to Grow: Should You Buy?
11:06am, Wednesday, 24'th Jul 2024
Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK Blenrep Combos for Multiple Myeloma Accepted for EU Review
11:21am, Monday, 22'nd Jul 2024
GSK announces the acceptance of its regulatory filing, seeking the approval of Blenrep combinations for the treatment of relapsed or refractory multiple myeloma, for review in the EU.
Is GSK a Top-Value Stock Right Now?
08:00am, Wednesday, 17'th Jul 2024
GSK stock has a long track record of lagging behind the broader markets. Under CEO Emma Walmsley, the drugmaker has made significant strides toward improving its core-value proposition to shareholders
